Dr. Wang received his B.S. from the School of Basic Medical Sciences at Peking University (2009) and his Ph.D. in Organic Chemistry from the College of Chemistry and Molecular Engineering at Peking University (2014). He began his postdoctoral training (2015) in the Department of Pharmacology at Johns Hopkins University, where he applied chemical biology approaches to target identification. In 2019, he joined Dr. Hui Zhang’s laboratory and has since focused on developing and applying proteogenomic and multi-omic strategies, spanning single-cell profiling to large, clinically annotated tumor cohorts, with particular emphasis on pancreatic neoplasms (including precursor lesions) and gastric cancer. His overarching goal is to build biologically grounded, clinically actionable models by integrating tumor tissue profiling with matched clinical and pathologic data to enable more precise risk stratification, earlier detection, and improved therapeutic decision-making. He advances the research through active participation in multiple NCI programs, including the Clinical Proteomic Tumor Analysis Consortium (CPTAC), the Early Detection Research Network (EDRN), and the Pancreatic Cancer Detection Consortium (PCDC).